TABLE 1.
Baseline demographics at time of bronchoalveolar lavage
| Stable IPF | Acute exacerbation of IPF | p-value | |
|---|---|---|---|
| Subjects n | 30 | 24 | |
| Age yrs | 65 ± 8 | 64 ± 9 | 0.91 |
| Male | 77% (23) | 79% (19) | 0.83 |
| Smoking history | |||
| Never-smoker | 27% (8) | 21% (5) | 0.62 |
| Former smoker | 60% (18) | 71% (17) | 0.41 |
| Current smoker | 13% (4) | 8% (2) | 0.56 |
| Current alcohol use | 43% (13) | 54% (13) | 0.43 |
| Body mass index | 24.5 ± 3.8 | 25.2 ± 4.0 | 0.56 |
| Comorbidities | |||
| CAD | 3% (1) | 13% (3) | 0.20 |
| GERD | 0% (0) | 8% (2) | 0.11 |
| OSA | 0% (0) | 0% (0) | |
| PH | 7% (2) | 4% (1) | 0.69 |
| Medications | |||
| Prednisone# | 17% (10) | 63% (15) | <0.01 |
| PPI | 0% (0) | 4% (1) | 0.23 |
| H2 blockers | 20% (6) | 38% (9) | 0.15 |
| Oestrogen | 0% (0) | 4% (1) | 0.26 |
| TLC % pred | 78.5 ± 12.0 | NA | |
| FVC % pred | 79.6 ± 16.4 | NA | |
| DL,CO % predicted | 68.8 ± 17.4 | NA | |
| Intubated¶ | 0% (0) | 8% (2) | 0.11 |
Data are presented as % (n) or mean ± sd, unless otherwise stated. IPF: idiopathic pulmonary fibrosis; CAD: coronary artery disease; GERD: gastrooesophageal reflux disease; OSA: obstructive sleep apnoea; PH: pulmonary hypertension; PPI: proton pump inhibitor; H2: histamine 2 receptor; TLC: total lung capacity; % pred: % predicted; FVC: forced vital capacity; DL,CO: diffusing capacity of the lung for carbon monoxide.
#
: prednisone use at the time of bronchoalveolar lavage;
¶
: intubated state at the time of bronchoalveolar lavage.